Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 31 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab May 17, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan December 15, 2020 Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... May 7, 2021 FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell... July 11, 2025 Load more HOT NEWS Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... New tool to tackle gaps in public’s knowledge of blood cancer... Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint...
